BRPI1007093A2 - fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer - Google Patents

fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer

Info

Publication number
BRPI1007093A2
BRPI1007093A2 BRPI1007093A BRPI1007093A BRPI1007093A2 BR PI1007093 A2 BRPI1007093 A2 BR PI1007093A2 BR PI1007093 A BRPI1007093 A BR PI1007093A BR PI1007093 A BRPI1007093 A BR PI1007093A BR PI1007093 A2 BRPI1007093 A2 BR PI1007093A2
Authority
BR
Brazil
Prior art keywords
diagnose
monitor
detect
predict
pde4d7
Prior art date
Application number
BRPI1007093A
Other languages
English (en)
Portuguese (pt)
Inventor
j p henderson David
D Houslay Miles
Hoffmann Ralf
Original Assignee
Koninl Philips Electronics Nv
Univ Glasgow Court
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninl Philips Electronics Nv, Univ Glasgow Court filed Critical Koninl Philips Electronics Nv
Publication of BRPI1007093A2 publication Critical patent/BRPI1007093A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04017—3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI1007093A 2009-05-12 2010-05-11 fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer BRPI1007093A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159960 2009-05-12
PCT/IB2010/052073 WO2010131195A1 (en) 2009-05-12 2010-05-11 Phosphodiesterase 4d7 as prostate cancer marker

Publications (1)

Publication Number Publication Date
BRPI1007093A2 true BRPI1007093A2 (pt) 2017-06-06

Family

ID=40843709

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007093A BRPI1007093A2 (pt) 2009-05-12 2010-05-11 fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer

Country Status (10)

Country Link
US (1) US8753892B2 (enExample)
EP (2) EP3434787B1 (enExample)
JP (4) JP6148007B2 (enExample)
KR (1) KR101778036B1 (enExample)
CN (2) CN102549167B (enExample)
BR (1) BRPI1007093A2 (enExample)
DK (1) DK2430191T3 (enExample)
ES (1) ES2700877T3 (enExample)
RU (1) RU2651474C2 (enExample)
WO (1) WO2010131195A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3343647B2 (ja) 1997-07-22 2002-11-11 株式会社岡田建築デザインルーム 木造軸組在来構法による既存建物を、外部より鋼製受け梁と鋼製筋かいフレームにより耐震補強をなす架構
WO2010131195A1 (en) * 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 4d7 as prostate cancer marker
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
CN102893392B (zh) 2010-04-13 2015-08-05 Gan系统公司 采用孤岛拓扑结构的高密度氮化镓器件
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
GB201504763D0 (en) 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
JP6745820B2 (ja) 2015-05-29 2020-08-26 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がん予後判定の方法
CN105893782A (zh) * 2016-05-26 2016-08-24 江苏省人民医院 前列腺癌风险预测装置
GB201616439D0 (en) 2016-09-28 2016-11-09 Mironid Limited Compounds and uses
CN106544430A (zh) * 2016-11-04 2017-03-29 叶伟亮 一种检测前列腺癌的分子标记物及其应用
ES2893469T3 (es) 2016-12-01 2022-02-09 Koninklijke Philips Nv Puntuaciones de riesgo basadas en la expresión de la variante 7 de la fosfodiesterasa 4D humana
EP3450981A1 (en) * 2017-08-28 2019-03-06 Trizell GmbH Btnl8 as a marker for tregs
HUE066292T2 (hu) * 2017-11-03 2024-07-28 Oxford BioDynamics PLC Az immunválasz genetikai szabályozása kromoszóma-kölcsönhatások által
DE102017125780B3 (de) * 2017-11-05 2018-12-13 Dimo Dietrich Verfahren zur Bestimmung des Ansprechens einer malignen Erkrankung auf eine Immuntherapie
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
WO2019158825A1 (en) * 2018-02-16 2019-08-22 Tampereen Korkeakoulusäätiö SR Xrcc5 as biomarker for prostate cancer
GB201805527D0 (en) 2018-04-04 2018-05-16 Mironid Ltd Compounds and their use as pde4 activators
KR20220008175A (ko) * 2020-07-13 2022-01-20 가톨릭대학교 산학협력단 전립선암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커
CN112779348B (zh) * 2020-12-31 2022-05-20 四川农业大学 一种小麦单位面积穗数主效qtl位点及紧密连锁的kasp引物和应用
EP4360711A1 (en) * 2022-10-27 2024-05-01 Koninklijke Philips N.V. Treatment of prostate cancer by promoting pde4d7
WO2024088865A1 (en) 2022-10-27 2024-05-02 Koninklijke Philips N.V. Treatment of prostate cancer by promoting pde4d7
EP4600377A1 (en) 2024-02-12 2025-08-13 Koninklijke Philips N.V. Prediction of an outcome of a subject suffering from a glioma
WO2025016918A1 (en) 2023-07-18 2025-01-23 Koninklijke Philips N.V. Prediction of an outcome of a subject suffering from a glioma
EP4620461A1 (en) 2024-03-22 2025-09-24 Koninklijke Philips N.V. Treatment of prostate cancer by inhibiting short pde4d isoforms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
BR0116852A (pt) * 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados biarilados de nicotinamida úteis como inibidores de isozimas pde4
IS7221A (is) * 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
US20030220273A1 (en) * 2002-05-15 2003-11-27 Isis Pharmaceuticals Inc. Antisense modulation of phosphodiesterase 4D expression
AU2003301894A1 (en) * 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2004042390A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
EP1426767A1 (en) 2002-12-04 2004-06-09 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (PDE4C)
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2004090157A1 (en) * 2003-04-10 2004-10-21 F. Hoffmann-La Roche Ag The use of pde4d in the screening for medicaments against atherosclerosis
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JP2009537118A (ja) * 2006-05-19 2009-10-29 トピジェン・ファーマシューティカルズ・インコーポレーテッド ホスホジエステラーゼの発現に影響するオリゴヌクレオチド
WO2008009479A1 (en) * 2006-07-21 2008-01-24 Epigenomics Ag Methods and nucleic acids for analyses for cellular proliferative disorders
JP5470041B2 (ja) 2006-10-10 2014-04-16 ザ ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド Ｅｒｇ遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
AU2008328222A1 (en) * 2007-11-23 2009-05-28 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
WO2010131195A1 (en) * 2009-05-12 2010-11-18 Koninklijke Philips Electronics N.V. Phosphodiesterase 4d7 as prostate cancer marker
WO2014145984A1 (en) * 2013-03-15 2014-09-18 Iris International Inc. Method and composition for staining and sample processing

Also Published As

Publication number Publication date
EP2430191A1 (en) 2012-03-21
EP2430191B1 (en) 2018-09-19
JP2017184729A (ja) 2017-10-12
US20120065148A1 (en) 2012-03-15
CN102549167A (zh) 2012-07-04
WO2010131195A1 (en) 2010-11-18
DK2430191T3 (en) 2018-12-10
RU2651474C2 (ru) 2018-04-19
JP6105012B2 (ja) 2017-03-29
RU2011150279A (ru) 2013-06-20
JP6430560B2 (ja) 2018-11-28
JP6148007B2 (ja) 2017-06-14
ES2700877T3 (es) 2019-02-19
EP3434787B1 (en) 2024-10-09
CN107267482A (zh) 2017-10-20
KR20120034651A (ko) 2012-04-12
JP2012526545A (ja) 2012-11-01
JP2019059733A (ja) 2019-04-18
CN102549167B (zh) 2017-04-26
US8753892B2 (en) 2014-06-17
EP3434787A1 (en) 2019-01-30
KR101778036B1 (ko) 2017-09-14
JP2016034277A (ja) 2016-03-17

Similar Documents

Publication Publication Date Title
BRPI1007093A2 (pt) fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer
ES2644277T3 (es) Métodos de diagnóstico para determinar la prognosis del cáncer de pulmón de células no pequeñas
BR112014009643A2 (pt) métodos para diagnosticar ou detectar neoplasia colorretal em um sujeito humano, biomarcador para progressão de doença e kits para um diagnóstico de neoplasia colorretal
BR112013002279A2 (pt) ensaios de biomacador para detectar ou medir inibição de atividade de tor quinase
IL254062B (en) Kits containing ptk7 antibody and their use in the treatment, detection, diagnosis or monitoring of cancer
EP2340555A4 (en) PROBE BLOCK ARRANGEMENT
IL233098A (en) Methods for detecting cancer and determining prognosis and survival probabilities and ratio based biomarkers for use therein
PL2438445T3 (pl) Sposoby diagnozowania raków gruczołu krokowego
BRPI0915086A2 (pt) detecção do uso de canabis
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
BRPI1011321A2 (pt) dispositivo de monitoramento de analito de métodos de uso
BRPI0913733A2 (pt) Artigos para detecção de células, dispositivo de aquisição de amostra, kit e métodos para detecção de células
PL2733492T3 (pl) Sposób wykrywania nowotworów
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112013016708A2 (pt) otimização de análise multigene de amostras de tumor
BR112012030587A2 (pt) métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador
EP2625531A4 (en) Improved sample test cards
BRPI0908669A2 (pt) dispositivo para coletas de amostras e métodos de uso
IT1406051B1 (it) Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
BR112013010272A2 (pt) métodos analíticos e arranjos para uso nos mesmos
EP2402875A4 (en) Noise analysis design method
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
BRPI0924180A2 (pt) lacases e métodos de uso das mesmas em baixa temperatura
IL245936A0 (en) Methods for the treatment of blood cancer and the use of biomarkers as predictors of clinical sensitivity to immunomodulatory treatments

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

B25G Requested change of headquarter approved

Owner name: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]